Literature DB >> 11105796

Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.

Y Kanno1, H Okada, T Saruta, H Suzuki.   

Abstract

BACKGROUND: The relative importance of hypertension in the progression of renal failure is well understood. Recently, several studies have provided evidence that antihypertensive therapy enhances renal survival. However, the specific antihypertensive drug regimens that are most effective in generating such long-term effects remain controversial. PATIENTS AND METHODS: Forty-nine hypertensive IgA nephropathy (IgAN) patients (39 +/- 7 years old, serum creatinine 1.1 +/- 0.2 mg/dl) with proteinuria received antihypertensive therapy with angiotensin-converting enzyme inhibitors (ACEi: 2.5-10 mg of benazapril daily) and calcium channel blockers (CCBs: 2.5-10 mg amlodipine daily) for 3 years. The patients' blood pressures in group one were controlled below 140/85 mmHg by increases in their first drug dose or by addition of the second drug in group 1. Blood pressures for patients in group 2 were controlled using the same two options, except to levels below 130/70 mmHg. Patients within the two groups were selected and controlled with regard to sex, age, and serum creatinine. The renal protective effects of each protocol were evaluated in terms of reductions in creatinine clearance. After 3 years of the above outlined blood pressure control regimens, the reductions in creatinine clearance were compared.
RESULTS: Creatinine clearances decreased in group 1 patients (from 85.7 +/- 2.4 ml/min to 72.9 +/- 2.4 ml/min, p < 0.05). On the other hand, creatinine clearance remained essentially unchanged for patients in group 2 (from 87.2 +/-4.7 ml/min to 85.9 +/- 5.9 ml/min). Although creatinine clearance in both groups was almost the same at the start of study, there was a significant difference between them by the conclusion of the study (p < 0.05). Proteinuria and hematuria did not change significantly throughout the study and there were no significant differences in these respects between these two corresponding groups. There were no significant differences between the groups with reference to side-effects or complications.
CONCLUSION: These data provide evidence that reducing blood pressure has protective renal effects in cases of mild renal insufficiency with hypertension in IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105796

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

1.  Predicting the risk for dialysis or death in IgA nephropathy.

Authors:  François Berthoux; Hesham Mohey; Blandine Laurent; Christophe Mariat; Aida Afiani; Lise Thibaudin
Journal:  J Am Soc Nephrol       Date:  2011-01-21       Impact factor: 10.121

Review 2.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

Review 3.  [Treatment of glomerulonephritis].

Authors:  T Risler; N Braun; C M Erley
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

Review 4.  [IgA nephropathy: frequent, but rarely diagnosed].

Authors:  J Floege; H-J Gröne
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

5.  Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.

Authors:  Cristina Sarcina; Carmine Tinelli; Francesca Ferrario; Bianca Visciano; Antonello Pani; Annalisa De Silvestri; Ilaria De Simone; Lucia Del Vecchio; Veronica Terraneo; Silvia Furiani; Gaia Santagostino; Enzo Corghi; Claudio Pozzi
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

6.  Clinical Features, Treatment and Prognostic Factors of Post-Transplant Immunoglobulin A Nephropathy.

Authors:  Diogo Buarque Cordeiro Cabral; Tainá Veras de Sandes-Freitas; José Osmar Medina-Pestana; Gianna Mastroianni-Kirsztajn
Journal:  Ann Transplant       Date:  2018-03-09       Impact factor: 1.530

7.  Left ventricular myocardial mass index associated with cardiovascular and renal prognosis in IgA nephropathy.

Authors:  Balázs Sági; István Késői; Tibor Vas; Botond Csiky; Judit Nagy; Tibor József Kovács
Journal:  BMC Nephrol       Date:  2022-08-16       Impact factor: 2.585

8.  Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy.

Authors:  Yoshio Horita; Masato Tadokoro; Kouichi Taura; Ryuichi Ashida; Mayumi Hiu; Takashi Taguchi; Akira Furusu; Shigeru Kohno
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

9.  Chapter 10: Immunoglobulin A nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.